Tclin SOST Sclerostin

Protein Summary

Description

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• Q9BQB4
• Q495N9

Gene Name

• SOST

Ensembl ID

• ENST00000301691
• ENSP00000301691
• ENSG00000167941

Symbol

• CDD
• VBCH
• DAND6
• SOST1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological term	0.92
biological process	0.66
microRNA	0.62
transcription factor	0.62
phenotype	0.61

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1533.91   (req: < 5)

Gene RIFs: 303   (req: <= 3)

Antibodies: 505   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1533.91   (req: >= 5)

Gene RIFs: 303   (req: > 3)

Antibodies: 505   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 11

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 16

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 1